Sodium Valproate-loaded Nanospanlastics in Patchy Alopecia Areata in Comparison to Topical Steroids

• Status: Not yet recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

the aim of this study is to assess the efficacy and safety of sodium valproate-loaded nanospanlastic in the treatment of patchy AA, in comparison to conventional therapy with topical steroids

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kasr El Aini Hospital
• Treatments: Mometasone Furoate; Valproic Acid

Criteria

Inclusion Criteria:

• Patients with mild to moderate patchy alopecia areata, which is defined as less than 50% involvement of the entire scalp

• Age above 12 years.

• Both genders.

• Patients with patchy alopecia areata, with 2 patches or more

Exclusion Criteria:

• Patients having single patch alopecia areata (at least 2 patches are required, as one patch will be left untreated to exclude the possibility of spontaneous remission)

• Affection of more than 50% of the scalp area

• Patients with alopecia totalis or universalis

• Patients with ophiasis

• Age: Less than 12 years old.

• Pregnant or lactating females

• Patients with history of or existing scalp skin diseases, infections or skin cancer

• Severe systemic illness (as uncontrolled DM or hypertension, liver or renal diseases) and immune-compromised patients

• Patients with concomitant autoimmune diseases as suspected by history or confirmed by previous investigations

• Diagnosis or history of local dermatological disease in the scalp apart from AA such as eczema, seborrheic dermatitis, psoriasis.

• Any psychiatric illness or psychological state impairing future compliance or influencing expectations of the patient